Migraine vs. Tension Headache: Aura, CGRP Pathway, Triggers, and Abortive Treatments
Headache is one of the most common neurological complaints and often leads to overuse of medications when migraines are misdiagnosed as tension headaches. This review will look at the pathophysiology of the trigeminovascular system, sensory aura mechanisms, diagnostic criteria (ICHD-3), acute abortive medications (triptans/gepants) and current CGRP monoclonal antibody therapies.
Hands-free audio narration
This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.
Quick Summary & Key Findings
Tension headaches are characterized by non-throbbing, bilaterally distributed pain felt as a ‘tight band’ around the head. They are accompanied by no nausea or photophobia and can be exacerbated by muscular tension and posture. Migraines are neurovascular events causing unilateral moderate/severe throbbing sensations. Patients are typically very sensitive to stimuli (photophobia/phonophobia) and experience nausea/vomiting. Symptoms are exacerbated by routine physical activity. Between 25-30% of patients will experience visual or sensory aura preceding a migraine. Acute treatments include triptans (sumatriptan) and CGRP antagonists (rimegepant/ubrogepant).
Headache disorders are ranked in the top ten most disabling diseases of the world; migraine alone affects over 1 billion people globally. Primary headaches are commonly mis-diagnosed and many people with symptoms of facial pressure and nasal congestion will assume they are suffering from sinus headaches. In reality, more than 80% of these people are found to be suffering from migraines.
Tension headaches are generally caused by myofascial tension in the pericranial muscles and increased central sensitisation. Migraine however is a complicated neurological disease that involves central hypersensitivity in the brain (genetically predisposed), cortical spreading depression and activation of the trigeminovascular system which results in the release of inflammatory neuropeptides.
Correct diagnosis of headaches allows patients to avoid taking ineffective analgesics and take specific neurochemical abortive and preventative treatments.
Diagnostic Differentiation: ICHD-3 Criteria
Neurobiology: Cortical Spreading Depression and CGRP
Modern Acute Abortive and Preventive Therapies
Cortical Spreading Depression, CGRP Biology & Phase III Monoclonal Trials
Acute Abortive Stratification, Triptan Titration & Cardiovascular Precautions
Diagnostic Algorithm: ICHD-3 Differential Matrix & Red-Flag SNOOP4 Triage
Therapeutic Comparison: First-Line Abortive & Preventive Migraine Medications
| Therapeutic Class | Representative Agent | Mechanism of Action | Clinical Onset | Key Clinical Considerations |
|---|---|---|---|---|
| 5-HT1B/1D Agonist (Triptan) | Sumatriptan (50–100mg oral, 6mg SC) | Selective agonist of vascular 5-HT1B and neuronal 5-HT1D receptors; inhibits trigeminal CGRP release and induces cranial vasoconstriction | 15–30 mins (SC/nasal) or 45–60 mins (oral) | First-line acute abortive; strictly contraindicated in coronary artery disease, stroke/TIA, peripheral vascular disease, or uncontrolled stage 2 hypertension. |
| Oral CGRP Antagonist (Gepant) | Rimegepant (75mg oral ODT) | Competitively binds calcitonin gene-related peptide (CGRP) receptor; blocks neurogenic vasodilation and neurogenic inflammation | 60 minutes | Zero coronary vasoconstriction; safe in cardiovascular disease; dual-indicated for acute treatment and every-other-day episodic migraine prevention. |
| 5-HT1F Receptor Agonist (Ditan) | Lasmiditan (50–100mg oral) | Selectively targets 5-HT1F receptors on trigeminal sensory neurons without activating 5-HT1B vasoconstrictive receptors | 45–60 minutes | Non-vasoconstrictive option for vascular disease patients; carries mandatory 8-hour driving restriction due to central nervous system sedative side effects. |
| Subcutaneous CGRP Monoclonal | Erenumab (70–140mg monthly) | Human monoclonal antibody that specifically binds and inhibits the canonical CGRP receptor complex | Monthly subcutaneous injection | First-line biologic preventative for chronic or frequent episodic migraine; monitor for new-onset or worsening constipation and arterial hypertension. |
| Beta-Adrenergic Blocker | Propranolol (80–240mg daily) | Non-selective beta-1 and beta-2 adrenergic receptor blocker; stabilizes central catecholaminergic tone and raises cortical spreading depression threshold | Daily oral maintenance | Level A evidence for migraine prophylaxis; caution in reactive airway disease/asthma, symptomatic bradycardia, and high-degree AV block. |
Frequently Asked Questions
Dr. Naresh Trehan, MBBS, MD, FACS
Chairman & Chief Cardiac Surgeon, Medanta – The Medicity • MBBS, MD (Cardiothoracic Surgery), FACSDr. Naresh Trehan is a world-renowned cardiovascular and cardiothoracic surgeon, Founder, and Chairman of Medanta – The Medicity, Gurugram. With over 40 years of pioneering surgical experience, he has performed more than 48,000 successful open-heart surgeries and leads cardiovascular clinical literacy at mediguide4u.
References & Clinical Resources
- Clinical Research Faculty & Editorial Team. The International Classification of Headache Disorders 3rd Edition (ICHD-3) (2020-2026). [Access Resource Link] — Cephalalgia / International Headache Society
- Clinical Research Faculty & Editorial Team. The American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice (2020-2026). [Access Resource Link] — Headache: The Journal of Head and Face Pain
- Clinical Research Faculty & Editorial Team. Calcitonin Gene-Related Peptide (CGRP) and Migraine Pathophysiology (2020-2026). [Access Resource Link] — Nature Reviews Neurology
Related Healthcare Guides
The Science of Stress Management: Neurobiology, Cortisol Regulation, and Clinical Techniques
Obstructive Sleep Apnea (OSA): STOP-Bang Screening, CPAP Therapy, and Heart Health
Major Depressive Disorder (MDD): Clinical Symptoms, Neurotransmitters, and Therapy
Reader Reviews & Clinical Q&A
Real experiences, reader questions, and verified physician guidance.
The neurobiological breakdown of the HPA axis, cortisol dysregulation, and amygdala reactivity helped me understand that chronic burnout is a physiological condition, not a personal failing.
Understanding the biological basis of chronic autonomic nervous system stress helps dismantle shame and guides effective, restorative recovery protocols, Jonathan.
Clear, compassionate, and scientifically rigorous. The comparison between cognitive behavioral exposure therapy and pharmacotherapy provides great balanced guidance for my clients.
Thank you, Megan. Presenting both psychotherapy and evidence-based medical treatments neutrally allows individuals to make informed collaborative decisions with their providers.